Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-06-21

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited medicines, shares CASGEVY economics with Vertex, and advances wholly owned in vivo and cell-therapy programs.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, but second franchise still matters

One approved gene-editing therapy and a strong cash balance support upside, but the rerating still depends on turning launch momentum into clearer economics and validating at least one owned follow-on franchise by 2031.

Analysis

Thesis

CRISPR Therapeutics already has first-product proof; if it turns CASGEVY into steadier commercial economics and validates one owned follow-on franchise by 2031, the stock can rerate from cash-plus-optionality to a credible multi-asset gene-editing platform.

Last Economy Alignment

AI helps target selection, construct design and portfolio speed, while CRISPR owns regulated IP, clinical data and manufacturing know-how. But value still clears through approvals, treatment logistics and partner economics, so this is helpful rather than transformative.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.9x (from 5 most recent analyses)

Reasoning

The upside case is a platform rerating, not a heroic all-programs-win scenario. One approved product already gives clinical credibility, so the stock does not need every pipeline asset to succeed; it needs CASGEVY economics to become dependable and at least one owned program to become clearly underwritable. If that happens, investors can value CRISPR as a real multi-franchise editing company instead of mostly cash plus distant options.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not immediate liquidity; it is proof conversion. If CASGEVY patient-journey demand does not translate into repeatable economics and the 2026-2027 pipeline fails to validate a second durable franchise, investors can keep valuing CRSP as net cash plus a partner-mediated approved asset rather than a broad gene-editing platform.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material clinical or commercial press release was posted between June 11 and June 21, 2026, so the thesis is unchanged but still waiting on execution proof.
With no formal CTX340 clinic-entry disclosure by June 21, 2026, the guided first-half 2026 window is effectively at deadline, raising near-term schedule sensitivity.
No new CASGEVY conversion metrics have been disclosed since the May 4, 2026 business update, so the market still lacks fresh evidence on patient-journey to revenue throughput.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.46

They own hard-to-copy biology, clinical data and manufacturing know-how, and each successful patient can make doctors, payers and regulators more comfortable with the next program. AI helps them design faster, but it cannot shortcut safety, treatment logistics or dependence on a partner-led lead product.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$83.74

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research